��ɫ��

��ɫ��

Events

Resources For

Abstract Details

Title A Phase 1 Study Evaluating ABT-414 with Temozolomide (TMZ) or Concurrent Radiotherapy (RT) and TMZ in Glioblastoma (GBM)

Topic Neuro-oncology

Presentation(s) (-)

Poster/Presentation
Number 006

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Andrew B. Lassman, MD, FAAN (Columbia University Irving Medical Center) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Ryan T. Merrell, MD (NorthShore University HealthSystem)	No disclosure on file
Martin Van Den Bent	Martin Van Den Bent has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Servier. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genenta. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fore Biotherapeutics. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Incyte. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Chimerix. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Servier. Martin Van Den Bent has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for European Journal of Cancer. Martin Van Den Bent has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neuro-Oncology.
Priya U. Kumthekar, MD	Dr. Kumthekar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biocept. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Enclear. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Affinia Therapeutics. Dr. Kumthekar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Janssen. Dr. Kumthekar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orbus Therapeutics. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bioclinica. Dr. Kumthekar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novocure. Dr. Kumthekar has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kumthekar has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bioclinica. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Servier. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BPGbio. Dr. Kumthekar has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Seagen.
Andrew Scott	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
David Reardon (Center for Neuro-Oncology)	No disclosure on file